EMBLEM Technology Transfer GmBH Managing Director
Dr. Lamm (born 1967 in Budapest) is a graduate of Edinburgh University (Biochemistry) and holds a Ph.D. in Molecular Biology.
After spending three years as a research scientist at the Boehringer Ingelheim Institute of Molecular Pathology (IMP) in Vienna, Dr. Lamm joined Wacker Chemie, a major global supplier of silicone and polymer raw materials and semi-conductors. At Wacker Chemie, Dr. Lamm was Business-Team Leader in the division specialising in advanced ceramic components for high-tech applications. As of October 2000 he is Managing Director of EMBL Enterprise Management Technology Transfer GmbH (EMBLEM; http://www.embl-em.de), the wholly owned subsidiary of the European Molecular Biology Laboratory (EMBL; www.embl.org).
Dr. Lamm is an alumnus of the European Molecular Biology Laboratory Ph.D. program and of the Boehringer Ingelheim Fonds and is co-founder of the EMBL Technology Fund (ETF) [www.embl-ventures.com]. He is on the board of directors of the BioRegio RND e. V. (Heidelberg) and former vice-president (2002-2006) of the Association of European Science and Technology Transfer Professionals (ASTP).
EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is an affiliate and the commercial arm of the European Molecular Biology Laboratory (EMBL). EMBL established in 1974 is a basic research institute funded by public research funds from 20 member states, including most of the EU, Switzerland and Israel and the associate member state Australia. EMBLEM identifies, protects and commercialises the intellectual property developed in the EMBL-world, from EMBL-alumni and from non-EMBL third parties. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, pharmaceutical, IT and mechanical/electrical engineering markets.